Robert Alexander Ingram's Insider Trades & SAST Disclosures
Robert Alexander Ingram's most recent trade in Biocryst Pharmaceuticals Inc. was a trade of 2,259 Common Stock done at an average price of $8.8 . Disclosure was reported to the exchange on Feb. 28, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Robert Alexander Ingram.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals Inc. | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 8.85 per share. | 28 Feb 2023 | 2,259 | 100,198 (0%) | 0% | 8.8 | 19,992 | Common Stock |
| Black Diamond Therapeutics... | Robert Alexander Ingram | FORMER DIRECTOR | Grant, award, or other acquisition of securities at price $ 1.50 per share. | 16 Dec 2022 | 9,375 | 42,854 (0%) | 0% | 1.5 | 14,063 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 13.36 per share. | 30 Nov 2022 | 1,497 | 97,939 (0%) | 0% | 13.4 | 20,000 | Common Stock |
| Black Diamond Therapeutics... | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 2.62 per share. | 16 Sep 2022 | 6,584 | 33,479 (0%) | 0% | 2.6 | 17,250 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 13.90 per share. | 31 Aug 2022 | 1,438 | 96,442 (0%) | 0% | 13.9 | 19,988 | Common Stock |
| Black Diamond Therapeutics... | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 2.03 per share. | 17 Jun 2022 | 8,498 | 26,895 (0%) | 0% | 2.0 | 17,251 | Common Stock |
| Black Diamond Therapeutics... | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 30,022 | 30,022 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc. | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 12,866 | 95,004 (0%) | 0% | 0 | Common Stock | |
| Biocryst Pharmaceuticals Inc. | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 9.31 per share. | 31 May 2022 | 2,078 | 82,138 (0%) | 0% | 9.3 | 19,346 | Common Stock |
| Black Diamond Therapeutics... | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 3.02 per share. | 18 Mar 2022 | 5,795 | 18,397 (0%) | 0% | 3.0 | 17,501 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 16.61 per share. | 28 Feb 2022 | 1,128 | 80,060 (0%) | 0% | 16.6 | 18,736 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 12.06 per share. | 30 Nov 2021 | 1,554 | 78,932 (0%) | 0% | 12.1 | 18,741 | Common Stock |
| Black Diamond Therapeutics... | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 9.90 per share. | 17 Sep 2021 | 1,869 | 9,306 (0%) | 0% | 9.9 | 18,503 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 15.92 per share. | 31 Aug 2021 | 1,177 | 77,378 (0%) | 0% | 15.9 | 18,738 | Common Stock |
| Black Diamond Therapeutics... | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics... | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 12.95 per share. | 18 Jun 2021 | 1,255 | 7,437 (0%) | 0% | 12.9 | 16,252 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 15.77 per share. | 28 May 2021 | 1,188 | 76,201 (0%) | 0% | 15.8 | 18,735 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 40,000 | 40,000 | - | - | Automatic Stock Option Grant | |
| Black Diamond Therapeutics... | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 24.01 per share. | 18 Mar 2021 | 677 | 6,182 (0%) | 0% | 24.0 | 16,255 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 10.78 per share. | 26 Feb 2021 | 1,739 | 75,013 (0%) | 0% | 10.8 | 18,746 | Common Stock |
| Black Diamond Therapeutics... | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 34.29 per share. | 15 Dec 2020 | 505 | 5,505 (0%) | 0% | 34.3 | 17,316 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 5.11 per share. | 30 Nov 2020 | 3,669 | 73,274 (0%) | 0% | 5.1 | 18,749 | Common Stock |
| Black Diamond Therapeutics... | Robert Alexander Ingram | Director | Purchase of securities on an exchange or from another person at price $ 30.46 per share. | 30 Sep 2020 | 5,000 | 5,000 (0%) | 0% | 30.5 | 152,285 | Common Stock |
| Black Diamond Therapeutics... | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Sep 2020 | 29,842 | 29,842 | - | - | Stock Option (Right to Buy) | |
| Biocryst Pharmaceuticals Inc. | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 4.15 per share. | 31 Aug 2020 | 4,518 | 69,605 (0%) | 0% | 4.2 | 18,750 | Common Stock |
| Biocryst Pharmaceuticals Inc. | Robert Alexander Ingram | Director | Grant, award, or other acquisition of securities at price $ 4.50 per share. | 01 Jun 2020 | 4,171 | 65,087 (0%) | 0% | 4.5 | 18,749 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges